Glycemic effects of simvastatin: Where do we stand?
ABSTRACT In clinical practice, simvastatin is usually used in the treatment of dyslipidemia patients and those at risk of or with established cardiovascular disease. However, previous studies have shown that simvastatin has the potential to affect glycemic parameters as it reportedly reduced insulin...
Saved in:
Main Authors: | Nor Razida Razali (Author), Hasniza Zaman Huri (Author), Luqman Ibrahim (Author), Shireene Ratna Vethakkan (Author), Bashar Mudhaffar Abdullah (Author) |
---|---|
Format: | Book |
Published: |
Universidade de São Paulo,
2018-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Similar Items
-
Violence: where do we stand?
by: Wasantha Gunathunga
Published: (2001) -
Diabetes Care in Iran: Where We Stand and Where We Are Headed
by: Sina Noshad, et al.
Published: (2016) -
Phytotherapy for Cachexia: Where Do We Stand?
by: Kenny Kuchta, et al.
Published: (2020) -
Clinical Microbiology: where do we stand?
by: Alkiviadis Vatopoulos
Published: (2024) -
Maximizing neuroprotection: where do we stand?
by: Kuffler DP
Published: (2012)